High pathologic complete response in her-2-positive locally advanced breast cancer(LABC) after primary systemic chemotherapy with weekly docetaxel and epirubicin

被引：0
|
作者：
Chen, Shin-Cheh
Lin, Yung-Chang
Chang, Hsien-Kun
Hsueh, Swei
Leung, Wai-Man
Tsai, Chien-Sheng
Lo, Yung-Feng
Tsai, Hsiu-Pei
Shen, Shih-Che
Chen, Miin-Fu
机构：
[1] Chang Gung Mem Hosp, Dept Surg, Taipei 10591, Taiwan
[2] Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan
[3] Chang Gung Mem Hosp, Dept Diagnost Radiol, Taipei 10591, Taiwan
[4] Chang Gung Mem Hosp, Dept Radiat Oncol, Taipei 10591, Taiwan
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [1] High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin
    Chen, Shin-Cheh
    Chang, Hsien-Kun
    Lin, Yung-Chang
    Hsueh, Swei
    Cheung, Yun-Chung
    Leung, Wai-Man
    Tsai, Chien-Sheng
    Lo, Yung-Feng
    Tsai, Hsiu-Pei
    Shen, Shih-Che
    Chen, Miin-Fu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (02) : 99 - 105
  • [2] Docetaxel and epirubicin as neoadjuvant chemotherapy (CT) in locally advanced breast cancer (LABC).
    Alkhatib, F
    Alawadi, S
    Grohn, P
    Motawy, M
    Fayaz, S
    Patel, J
    Attia, N
    Trad, D
    Delvadia, M
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 21 - 22
  • [3] Epirubicin and Docetaxel as Primary Chemotherapy in Locally Advanced Breast Cancer
    Conti, F.
    Corsetti, S.
    Viola, G.
    Sperduti, I.
    Carpano, S.
    Pizzuti, L.
    Foggi, P.
    Perri, P.
    Anza, M.
    Toglia, G.
    Lopez, M.
    [J]. ONCOLOGY, 2009, 77 : 139 - 140
  • [4] Epirubicin and Cyclophosphamide Followed by Docetaxel as Primary Systemic Chemotherapy in Locally Advanced Breast Cancer
    Hirano, Akira
    Shimizu, Tadao
    Watanabe, Osamu
    Kinoshita, Jun
    Kimura, Kiyomi
    Kamimura, Mari
    Domoto, Kaoru
    Aiba, Motohiko
    Ogawa, Kenji
    [J]. ANTICANCER RESEARCH, 2008, 28 (6B) : 4137 - 4142
  • [5] Efficacy of chemotherapy(CT) adaptation according to pathologic response after primary chemotherapy (PCT) for locally advanced breast cancer (LABC)
    Delva, R
    Lortholary, A
    Gamelin, E
    Maillart, P
    Guerin, O
    Leynia, P
    Biville, F
    Larra, F
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 13 - 13
  • [6] Response rate with weekly epirubicin and docetaxel as neoadjuvant chemotherapy (NAC) for locally-advanced breast cancer (BC).
    Chen, SC
    Chang, HK
    Lin, YC
    Leung, WM
    Chang, JT
    Cheung, YC
    Hsueh, S
    Lo, YF
    Tsai, HP
    Chen, MF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 99S - 99S
  • [7] The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
    Zhang, Wei
    Tian, Huan
    Yang, Shi-hong
    [J]. ANALYTICAL CELLULAR PATHOLOGY, 2017, 2017
  • [8] High pathologic complete response after primary chemotherapy in patients treated with weekly paclitaxel followed by FEC chemotherapy with simultaneous trastuzumab in Her-2 positive operable breast cancer
    Pernas, S.
    Gil Gil, M.
    Urruticoechea, A.
    Fernandez-Ortega, A.
    Falo, C.
    Piulats, J. M.
    Prieto, L.
    Pla, M. J.
    Moreno, A.
    Germa, J. R.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 96 - 96
  • [9] NEOADJUVANT 3-WEEKLY EPIRUBICIN (EPI) PLUS DOCETAXEL (DOC) CHEMOTHERAPY (CT) IN LOCALLY ADVANCED BREAST CANCER (LABC): ACTIVITY, SAFETY AND PREDICTIVE FACTORS OF RESPONSE
    Strada, Maria Rosa
    Frascaroli, Mara
    Palumbo, Raffaella
    Bernardo, Antonio
    Villani, Laura
    Scelsi, Mario
    Jedrychowska, Ivona
    Albanese, Davide
    Teragni, Cristina
    Bernardo, Giovanni
    [J]. ANNALS OF ONCOLOGY, 2009, 20
  • [10] Induction preoperative chemotherapy with high-dose epirubicin in locally advanced breast cancer (LABC)
    Silvestro, P
    DAiuto, G
    Caparrotti, G
    Menditto, C
    Tambaro, R
    Rinaldi, L
    Pergola, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 713 - 713
12345